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Introduction
Canakinumab is a recombinant monoclonal fully human
antibody against Interleukin-1b and currently the only
drug approved for the treatment of CAPS in Europe.
Current dose recommendations are 150mg (body weight
>40kg) respectively 2mg/kg bodyweight (15 to 40kg)
every 8 weeks but yield insufficient response in some
individuals, especially in children and patients with
severe phenotypes [1].
Objectives
In this study we analyzed the response to daily practice
(in contrast to trial condition) canakinumab treatment
regimens in CAPS-patients with focus on age, mutation
and clinical presentation and the necessity and effect of
dose adjustment.
Methods
An observational national multicenter study was con-
ducted. CAPS-Patients were included if they received at
least two doses of canakinumab. Data included informa-
tion regarding demographics, treatment, clinical disease
activity and inflammatory markers (including SAA, CRP,
S100, ESR, IL-6). Response to treatment was assessed
using CAPS-disease activity scores, CRP and/or SAA
levels.
Results
A cohort of 68 patients with CAPS was analyzed. At the
beginning of treatment 27 patients had been younger
than 18 years with a median age of 25.4 years (range 22
months to 73 years). The most frequent mutations were
R260W, A439V, E311K, V198M, Q703K and most
patients showed MWS or FCAS/MWS phenotype
(3 patients with NOMID, 4 with MWS/NOMID). The
median treatment duration was 855 days (range:
28-1973 days). In 57% (39) of patients full response was
sustained until next scheduled drug application (34%
(23) partial remission). With standard treatment 31%
(21) of patients achieved full response. In 44% (30) of all
patients canakinumab dose and/or application interval
was increased above the standard regimen (2/3 NOMID,
3/4 MWS/NOMID). Two serious adverse events were
reported (severe infection, osteonecrosis), mild and
moderate adverse events were mostly upper respiratory
tract infections but almost no injection site reactions.
Conclusion
Most CAPS-Patients achieve full remission with canaki-
numab. However, almost 50% of patients, particularly
children, require dose adjustment. Dose increase was
well tolerated and full remission was achieved without
an increased rate of adverse events.
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